Abstract
Although immunotherapy (IO) has changed the paradigm for the treatment of patients
with advanced non-small cell lung cancers (aNSCLC), only around 30% to 50% of treated
patients experience a long-term benefit from IO. Furthermore, the identification of
the 30 to 50% of patients who respond remains a major challenge, as programmed Death-Ligand
1 (PD-L1) is currently the only biomarker used to predict the outcome of IO in NSCLC
patients despite its limited efficacy. Considering the dynamic complexity of the immune
system-tumor microenvironment (TME) and its interaction with the host's and patient's
behavior, it is unlikely that a single biomarker will accurately predict a patient's
outcomes. In this scenario, Artificial Intelligence (AI) and Machine Learning (ML)
are becoming essential to the development of powerful decision-making tools that are
able to deal with this high-complexity and provide individualized predictions to better
match treatments to individual patients and thus improve patient outcomes and reduce
the economic burden of aNSCLC on healthcare systems.
I3LUNG is an international, multicenter, retrospective and prospective, observational
study of patients with aNSCLC treated with IO, entirely funded by European Union (EU)
under the Horizon 2020 (H2020) program. Using AI-based tools, the aim of this study
is to promote individualized treatment in aNSCLC, with the goals of improving survival
and quality of life, minimizing or preventing undue toxicity and promoting efficient
resource allocation. The final objective of the project is the construction of a novel,
integrated, AI-assisted data storage and elaboration platform to guide IO administration
in aNSCLC, ensuring easy access and cost-effective use by healthcare providers and
patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Lung CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA: Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
- Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.”.Ann Oncol. 2019; 30: 863-870https://doi.org/10.1093/annonc/mdy474
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet. 2016; 387: 1540-1550https://doi.org/10.1016/S0140-6736(15)01281-7
- Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study.J Clin Oncol. 2018; 36: 1675-1684https://doi.org/10.1200/JCO.2017.77.0412
- Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.JAMA Oncol. 2018; 4: 1543-1552https://doi.org/10.1001/jamaoncol.2018.3676
- Hyperprogressive disease: recognizing a novel pattern to improve patient management.Nat Rev Clin Oncol. 2018; 15: 748-762https://doi.org/10.1038/s41571-018-0111-2
- Toward personalized treatment approaches for non-small-cell lung cancer.Nat Med. 2021; 27: 1345-1356https://doi.org/10.1038/s41591-021-01450-2
- EPSILoN: a prognostic score using clinical and blood biomarkers in advanced non–small-cell lung cancer treated with immunotherapy.Clin Lung Cancer. 2020; 0https://doi.org/10.1016/j.cllc.2019.11.017
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.Science. 2018; 362: eaar3593https://doi.org/10.1126/science.aar3593
- Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.Nat Commun. 2021; 12: 729https://doi.org/10.1038/s41467-021-20935-9
- A “Third Wheel” effect in health decision making involving artificial entities: a psychological perspective.Front Public Health. 2020; 8https://doi.org/10.3389/fpubh.2020.00117
- A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.Am J Transl Res. 2021; 13: 743-756
- DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy.NPJ Digit Med. 2021; 4: 14https://doi.org/10.1038/s41746-021-00381-z
- Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.Theranostics. 2021; 11: 2098-2107https://doi.org/10.7150/thno.48027
Article info
Publication history
Published online: February 27, 2023
Accepted:
February 15,
2023
Received in revised form:
February 15,
2023
Received:
September 29,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Inc.
